Hedge Fund - Deerfield Management

Deerfield Management, headquartered in New York, is a prominent American investment firm with a focus on healthcare and biotechnology. Renowned for its strategic investments, both public and private, Deerfield stands as a leading force in the global healthcare investment landscape, recognized as one of the largest and most influential dedicated firms in the industry.

James "Jim" E. Flynn joined Deerfield in 2000 and has since spearheaded the firm's evolution and growth. Under his stewardship, Deerfield has cultivated profound expertise in healthcare information through the establishment of the Deerfield Institute. Jim has also expanded the firm's investment horizons, encompassing venture and private structured financings. Furthermore, he has championed philanthropic efforts through the establishment of the Deerfield Foundation, dedicated to enhancing the well-being of underprivileged children. Jim's vision led to the inception of Deerfield Discovery and Development, LLC, which orchestrates the firm's discovery research initiatives. Additionally, he played a pivotal role in establishing a healthcare innovation center at 345 Park Avenue South in New York City. Before joining Deerfield, Jim garnered acclaim as a top-ranked analyst at Furman Selz, specializing in pharmaceutical and medical device companies. His tenure as Vice President of Corporate Development at Alpharma Inc. underscored his prowess in business development and strategic planning. Jim's journey in healthcare investing commenced at Kidder, Peabody & Co., where he ascended to the role of senior analyst covering the specialty pharmaceutical industry. Since 2009, Jim has chaired the Quality Committee of the Board of Trustees of Continuum Health Partners until its merger with Mount Sinai Health System in 2013. He continues to serve on the Board of Trustees at Mount Sinai. Additionally, Jim holds the position of Chairman of the Board of Trustees at the New York Academy of Medicine and is an esteemed member of the University of Michigan Life Sciences Institute Leadership Council. Jim is an alumnus of the University of Michigan, where he earned a B.S. in Cellular and Molecular Biology and Economics. He furthered his education with a M.S. in Biotechnology from Johns Hopkins University.

Deerfield Management Company manages discretionary assets totaling $16,117,395,447, as reported in their Form ADV dated March 2024. Their most recent 13F filing for the fourth quarter of 2023 unveiled $5,415,638,759 in managed 13F securities, with a significant concentration of 57.84% among their top 10 holdings. Among their notable holdings, Deerfield Management Company, L.P. (Series C)'s largest position is in Nuvalent Inc., with a substantial holding of 19,991,024 shares.